EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Treatment with the copper compound CuATSM has no significant effect on motor neuronal pathology in patients with ALS

Yue Yang, Dominic Rowe, Heather McCann, Claire E Shepherd iD, Jillian J Kril iD, Matthew C Kiernan, Glenda M Halliday iD, Rachel H Tan iD

Neuropathology and Applied Neurobiology · 2023

DOI: 10.1111/nan.12919 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuropathology and Applied Neurobiology, 2023. Verfasst von Yue Yang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Brain and Mind Centre, University of Sydney, Sydney, New South Wales, Australia. Hauptthemen laut MEDLINE: Amyotrophic Lateral Sclerosis. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAAA NIH HHS, National Health and Medical Research Council, FightMND.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Although the orally available brain‐penetrant copper compound CuATSM has demonstrated promising effects in SOD1‐linked mouse models, the impact of CuATSM on disease pathology in patients with amyotrophic lateral sclerosis (ALS) remains unknown.

Methods

The present study set out to address this deficit by performing the first pilot comparative analysis of ALS pathology in patients that had been administered CuATSM and riluzole [ N = 6 cases composed of ALS‐TDP ( n = 5) and ALS‐SOD1 ( n = 1)] versus riluzole only [ N = 6 cases composed of ALS‐TDP ( n = 4) and ALS‐SOD1 ( n = 2)].

Results

Our results revealed no significant difference in neuron density or TDP‐43 burden in the motor cortex and spinal cord of patients that had received CuATSM compared with patients that had not. In patients that had received CuATSM, p62‐immunoreactive astrocytes were observed in the motor cortex and reduced Iba1 density was found in the spinal cord. However, no significant difference in measures of astrocytic activity and SOD1 immunoreactivity was found with CuATSM treatment.

Discussion

These findings, in this first postmortem investigation of patients with ALS in CuATSM trials, demonstrate that in contrast to that seen in preclinical models of disease, CuATSM does not significantly alleviate neuronal pathology or astrogliosis in patients with ALS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Amyotrophic Lateral SclerosisMiceAnimalsCopperSuperoxide Dismutase-1RiluzoleSuperoxide DismutaseMotor NeuronsSpinal CordDNA-Binding ProteinsMice, TransgenicOrganocopper Compounds

Stichwörter der Autor:innen

TDP-43 pathologyamyotrophic lateral sclerosiscopper ATSM (CuATSM)p62 pathologyriluzole

Substanzen

CopperSuperoxide Dismutase-1RiluzoleSuperoxide DismutaseDNA-Binding ProteinsCuATSMOrganocopper Compounds

Autor:innen und Institutionen

  • Brain and Mind Centre, University of Sydney, Sydney, New South Wales, Australia.
  • Faculty of Medicine and Health, School of Medical Sciences, University of Sydney, Camperdown, New South Wales, Australia.
  • Macquarie University Centre for Motor Neuron Disease Research, Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, New South Wales, Australia.
  • Neuroscience Research Australia, Randwick, New South Wales, Australia.
  • Dementia Research Centre, Macquarie Medical School, Macquarie University, Sydney, New South Wales, Australia.
  • Institute of Clinical Neurosciences, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.

ORCID-Profile: Claire E Shepherd, Jillian J Kril, Glenda M Halliday, Rachel H Tan

Förderung

  • NIAAA NIH HHS
  • National Health and Medical Research Council
  • FightMND
  • Motor Neurone Disease Research Australia

Zitieren

APA

Yang, Y., Rowe, D., McCann, H., Shepherd, C. E., Kril, J. J., Kiernan, M. C., Halliday, G. M., & Tan, R. H. (2023). Treatment with the copper compound CuATSM has no significant effect on motor neuronal pathology in patients with ALS. Neuropathology and Applied Neurobiology. https://doi.org/10.1111/nan.12919

Vancouver

Yang Y, Rowe D, McCann H, Shepherd CE, Kril JJ, Kiernan MC, et al. Treatment with the copper compound CuATSM has no significant effect on motor neuronal pathology in patients with ALS. Neuropathology and Applied Neurobiology. 2023. doi:10.1111/nan.12919

BibTeX
@article{Yang2023,
  author = {Yang, Yue and Rowe, Dominic and McCann, Heather and Shepherd, Claire E and Kril, Jillian J and Kiernan, Matthew C and Halliday, Glenda M and Tan, Rachel H},
  title = {Treatment with the copper compound CuATSM has no significant effect on motor neuronal pathology in patients with ALS},
  journal = {Neuropathology and Applied Neurobiology},
  year = {2023},
  doi = {10.1111/nan.12919}
}
Kostenlos starten →